Literature DB >> 23954895

Targeting the sphingosine-1-phosphate axis in cancer, inflammation and beyond.

Gregory T Kunkel1, Michael Maceyka, Sheldon Milstien, Sarah Spiegel.   

Abstract

The bioactive lipid sphingosine-1-phosphate (S1P) is involved in multiple cellular signalling systems and has a pivotal role in the control of immune cell trafficking. As such, S1P has been implicated in disorders such as cancer and inflammatory diseases. This Review discusses the ways in which S1P might be therapeutically targeted - for example, via the development of chemical inhibitors that target the generation, transport and degradation of S1P and via the development of specific S1P receptor agonists. We also highlight recent conflicting results observed in preclinical studies targeting S1P and discuss ongoing clinical trials in this field.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23954895      PMCID： PMC3908769          DOI： 10.1038/nrd4099

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN： 1474-1776            Impact factor:   84.694


  142 in total

1.  Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists.

Authors:  Suzanne Mandala; Richard Hajdu; James Bergstrom; Elizabeth Quackenbush; Jenny Xie; James Milligan; Rosemary Thornton; Gan-Ju Shei; Deborah Card; CarolAnn Keohane; Mark Rosenbach; Jeffrey Hale; Christopher L Lynch; Kathleen Rupprecht; William Parsons; Hugh Rosen
Journal:  Science       Date:  2002-03-28       Impact factor: 47.728

Review 2.  Translational aspects of sphingosine 1-phosphate biology.

Authors:  Susan Pyne; Nigel J Pyne
Journal:  Trends Mol Med       Date:  2011-04-21       Impact factor: 11.951

Review 3.  Sphingosine-1-phosphate and lymphocyte egress from lymphoid organs.

Authors:  Jason G Cyster; Susan R Schwab
Journal:  Annu Rev Immunol       Date:  2011-12-05       Impact factor: 28.527

Review 4.  Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis.

Authors:  Volker Brinkmann; Andreas Billich; Thomas Baumruker; Peter Heining; Robert Schmouder; Gordon Francis; Shreeram Aradhye; Pascale Burtin
Journal:  Nat Rev Drug Discov       Date:  2010-10-29       Impact factor: 84.694

5.  Sphingosine 1-phosphate analogs as receptor antagonists.

Authors:  Michael D Davis; Jeremy J Clemens; Timothy L Macdonald; Kevin R Lynch
Journal:  J Biol Chem       Date:  2004-12-08       Impact factor: 5.157

6.  Flow-regulated endothelial S1P receptor-1 signaling sustains vascular development.

Authors:  Bongnam Jung; Hideru Obinata; Sylvain Galvani; Karen Mendelson; Bi-sen Ding; Athanasia Skoura; Bernd Kinzel; Volker Brinkmann; Shahin Rafii; Todd Evans; Timothy Hla
Journal:  Dev Cell       Date:  2012-09-11       Impact factor: 12.270

7.  Sphingosine kinase type 1 inhibition reveals rapid turnover of circulating sphingosine 1-phosphate.

Authors:  Yugesh Kharel; Thomas P Mathews; Amanda M Gellett; Jose L Tomsig; Perry C Kennedy; Morgan L Moyer; Timothy L Macdonald; Kevin R Lynch
Journal:  Biochem J       Date:  2011-12-15       Impact factor: 3.857

8.  Role for sphingosine kinase 1 in colon carcinogenesis.

Authors:  Toshihiko Kawamori; Tatsuya Kaneshiro; Masae Okumura; Samer Maalouf; Andre Uflacker; Jacek Bielawski; Yusuf A Hannun; Lina M Obeid
Journal:  FASEB J       Date:  2008-09-29       Impact factor: 5.191

9.  Sphingosine-1-phosphate-mediated osteoclast precursor monocyte migration is a critical point of control in antibone-resorptive action of active vitamin D.

Authors:  Junichi Kikuta; Shunsuke Kawamura; Fumie Okiji; Mai Shirazaki; Sadaoki Sakai; Hitoshi Saito; Masaru Ishii
Journal:  Proc Natl Acad Sci U S A       Date:  2013-04-08       Impact factor: 11.205

10.  Spns2, a transporter of phosphorylated sphingoid bases, regulates their blood and lymph levels, and the lymphatic network.

Authors:  Masayuki Nagahashi; Eugene Y Kim; Akimitsu Yamada; Subramaniam Ramachandran; Jeremy C Allegood; Nitai C Hait; Michael Maceyka; Sheldon Milstien; Kazuaki Takabe; Sarah Spiegel
Journal:  FASEB J       Date:  2012-11-24       Impact factor: 5.191
View more
  206 in total

1.  Poor Repair of Skeletal Muscle in Aging Mice Reflects a Defect in Local, Interleukin-33-Dependent Accumulation of Regulatory T Cells.

Authors:  Wilson Kuswanto; Dalia Burzyn; Marisella Panduro; Kathy K Wang; Young Charles Jang; Amy J Wagers; Christophe Benoist; Diane Mathis
Journal:  Immunity       Date:  2016-02-09       Impact factor: 31.745

Review 2.  Biological Effects of Naturally Occurring Sphingolipids, Uncommon Variants, and Their Analogs.

Authors:  Mitchell K P Lai; Wee Siong Chew; Federico Torta; Angad Rao; Greg L Harris; Jerold Chun; Deron R Herr
Journal:  Neuromolecular Med       Date:  2016-07-08       Impact factor: 3.843

3.  Downregulation of Critical Oncogenes by the Selective SK2 Inhibitor ABC294640 Hinders Prostate Cancer Progression.

Authors:  Randy S Schrecengost; Staci N Keller; Matthew J Schiewer; Karen E Knudsen; Charles D Smith
Journal:  Mol Cancer Res       Date:  2015-08-13       Impact factor: 5.852

4.  Transforming Sphingosine Kinase 1 Inhibitors into Dual and Sphingosine Kinase 2 Selective Inhibitors: Design, Synthesis, and in Vivo Activity.

Authors:  Elizabeth S Childress; Yugesh Kharel; Anne M Brown; David R Bevan; Kevin R Lynch; Webster L Santos
Journal:  J Med Chem       Date:  2017-04-25       Impact factor: 7.446

5.  Sphingosine-1-Phosphate Receptor-1 Promotes Environment-Mediated and Acquired Chemoresistance.

Authors:  Veronica Lifshitz; Saul J Priceman; Wenzhao Li; Gregory Cherryholmes; Heehyoung Lee; Adar Makovski-Silverstein; Lucia Borriello; Yves A DeClerck; Hua Yu
Journal:  Mol Cancer Ther       Date:  2017-07-17       Impact factor: 6.261

Review 6.  Sphingolipids in mitochondria.

Authors:  María José Hernández-Corbacho; Mohamed F Salama; Daniel Canals; Can E Senkal; Lina M Obeid
Journal:  Biochim Biophys Acta Mol Cell Biol Lipids       Date:  2016-09-30       Impact factor: 4.698

7.  Mechanisms of action of substituted β-amino alkanols on Leishmania donovani.

Authors:  María Ángeles Abengózar; Luis A Bustos; Raquel García-Hernández; Pilar Fernández de Palencia; Ricardo Escarcena; Santiago Castanys; Esther del Olmo; Francisco Gamarro; Arturo San Feliciano; Luis Rivas
Journal:  Antimicrob Agents Chemother       Date:  2014-12-08       Impact factor: 5.191

Review 8.  Non-coding RNAs: the new central dogma of cancer biology.

Authors:  Phei Er Saw; Xiaoding Xu; Jianing Chen; Er-Wei Song
Journal:  Sci China Life Sci       Date:  2020-09-11       Impact factor: 6.038

Review 9.  Targeting sphingosine-1-phosphate signaling in lung diseases.

Authors:  David L Ebenezer; Panfeng Fu; Viswanathan Natarajan
Journal:  Pharmacol Ther       Date:  2016-09-13       Impact factor: 12.310

Review 10.  Sphingolipids in neurodegeneration (with focus on ceramide and S1P).

Authors:  Guanghu Wang; Erhard Bieberich
Journal:  Adv Biol Regul       Date:  2018-09-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.